Funding from Cancer Prevention and Research Institute of Texas has brought more than 324 distinguished cancer researchers to Texas.

Hepatocellular carcinoma continues to pose a diagnostic challenge, particularly in the setting of underlying pathomorphological changes in the liver due to cirrhosis, steatosis, or steatohepatitis.

Researchers say if their results are confirmed through further study they are optimistic the approach could be used to treat chronic infections for the first time.

Ficerafusp alfa enters phase 2/3 trial for recurrent/metastatic head and neck cancer, evaluating its combination with ...

Renal + Urology News highlighted research led by the University of Cincinnati's Alberto Martini, MD, that found using ...

Hepatocellular carcinoma (HCC) is one of the deadliest cancers globally, with increasing incidence and mortality rates.

Luminescent gold nanoparticles (L-AuNPs) represent a novel class of luminescent nanomaterials that have attracted ...

Hepatocellular carcinoma (HCC) is one of the deadliest malignant tumors in the world, and its incidence and mortality have increased year by year. HCC research has increasingly focused on ...

IntroductionHepatocellular carcinoma (HCC) is one of the deadliest cancers globally, with increasing incidence and mortality rates. It arises from ...

The US FDA has granted fast track designation to Rznomics' RZ-001 for the treatment of hepatocellular carcinoma (HCC).

Our data indicate that hybrid cell vaccination is a safe and effective immune therapy for human metastatic renal cell carcinoma. This vaccination is an example of an individualized immune ...